|
Volume
7 Number 11
November 2019
|
|
Home
>
Disciplines
>
Publications
>
Prostate
Cancer Research
>
Volume
7, Year 2019
>
Number 11, November
|
|
|
CONTENTS
|
▼
|
|
DIAGNOSIS
ETIOLOGY,
PATHOGENESIS, PATHOLOGY
FOLLOW-UP,
SIDE EFFECTS, QUALITY OF LIFE
INTEGRATIVE
MEDICINE
OVERALL
MANAGEMENT
PROGNOSIS
TREATMENT
|
|
|
DIAGNOSIS
|
▲
|
|
Andriole GL.
What is the best PET target for early
biochemical recurrence of prostate cancer?
Lancet Oncol.
2019 Nov 1;20(11):e608. doi: 10.1016/S1470-2045(19)30586-8.
Source
.
Similar
articles
Refers
to: Calais J, et al., 18F-fluciclovine
PET-CT and 68Ga-PSMA-11
PET-CT in patients with early biochemical recurrence after
prostatectomy: a prospective, single-centre, single-arm,
comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294.
doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
Source
.
Similar
articles
|
|
|
|
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C,
Bach-Gansmo T, Fendler WP, Czernin J.
What is the best
PET target for early biochemical recurrence of prostate
cancer?-Authors' reply.
Lancet Oncol. 2019 Nov
1;20(11):e609-e610. doi: 10.1016/S1470-2045(19)30654-0.
Source
.
Similar
articles
Refers
to Andriole GL, What is the best PET target for early biochemical
recurrence of prostate cancer?
Lancet Oncol. 2019 Nov
1;20(11):e608. doi: 10.1016/S1470-2045(19)30586-8. Source
.
Similar
articles
|
|
|
|
England T, Li J, Cohen RJ.
Fifteen-year analysis of
prostate biopsies in Western Australia including recent impact of
multiparametric magnetic resonance imaging.
ANZ J Surg.
2019 Dec;89(12):1605-1609. doi: 10.1111/ans.15566. Epub 2019 Nov
25.
Source
.
Similar
articles
|
|
|
|
Kulkarni SC, Sundaram PS, Padma S.
In primary lymph nodal
staging of patients with high-risk and intermediate-risk prostate
cancer, how critical is the role of Gallium-68 prostate-specific
membrane antigen PET computed tomography?
Nucl Med
Commun. 2019 Nov 7. doi: 10.1097/MNM.0000000000001110. [Epub ahead
of print]
Source
.
Similar
articles
|
|
|
|
Turkbey B, Choyke PL.
18F-fluciclovine
PET or PSMA PET for prostate cancer imaging?
Nat Rev
Urol. 2020 Jan;17(1):9-10. doi: 10.1038/s41585-019-0255-6.
Source
.
Similar
articles
Refers
to: Calais J, et al., 18F-fluciclovine
PET-CT and 68Ga-PSMA-11
PET-CT in patients with early biochemical recurrence after
prostatectomy: a prospective, single-centre, single-arm,
comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294.
doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
Source
.
Similar
articles
|
|
|
ETIOLOGY,
PATHOGENESIS, PATHOLOGY
|
▲
|
|
Zhu M, Yu X, Zheng Z, Huang J, Yang X, Shi H.
Capsaicin
suppressed activity of prostate cancer stem cells by inhibition of
Wnt/β-catenin pathway.
Phytother Res. 2019 Nov 28.
doi: 10.1002/ptr.6563. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
FOLLOW-UP,
SIDE EFFECTS, QUALITY OF LIFE
|
▲
|
|
Rombouts AJM, Hugen N, Elferink MAG, Poortmans PMP, Nagtegaal ID,
de Wilt JHW.
Increased risk for second primary rectal
cancer after pelvic radiation therapy.
Eur J Cancer.
2020 Jan;124:142-151. doi: 10.1016/j.ejca.2019.10.022. Epub 2019
Nov 22.
Source
.
Similar
articles
|
|
|
INTEGRATIVE
MEDICINE
|
▲
|
|
Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC,
Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ,
Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci
E, Sweeney CJ, Finn SP, Mucci LA.
Statin use is
associated with lower risk of PTEN-null and lethal prostate
cancer.
Clin Cancer Res. 2019 Nov 21. doi:
10.1158/1078-0432.CCR-19-2853. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
OVERALL
MANAGEMENT
|
▲
|
|
Ganau M, Gallinaro P, Cebula H, Scibilia A, Todeschi J, Gubian A,
Nannavecchia B, Signorelli F, Pop R, Coca HA, Proust F, Chibbaro
S.
Intracranial Metastases from Prostate Carcinoma:
Classification, Management, and Prognostication.
World
Neurosurg. 2019 Oct 31. doi: 10.1016/j.wneu.2019.10.125. [Epub
ahead of print]
Source
.
Similar
articles
|
|
|
PROGNOSIS
|
▲
|
|
Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS.
Impact
of age at diagnosis of de novo metastatic prostate cancer on
survival.
Cancer. 2019 Nov 26. doi: 10.1002/cncr.32630.
[Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S,
Yu EY, Bournakis E, Sella A, Zagonel V, De Giorgi U, Tucci M,
Gelderblom H, Galli L, Pappagallo G, Bria E, Sperduti I, Oudard S;
CASTOR study investigators.
Survival Outcomes From a
Cumulative Analysis of Worldwide Observational Studies on
Sequential Use of New Agents in Metastatic Castration-Resistant
Prostate Cancer.
Clin Genitourin Cancer. 2019 Sep 27.
doi: 10.1016/j.clgc.2019.09.010. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Frankcombe DE, Li J, Cohen RJ.
Redefining the Concept of
Clinically Insignificant Prostate Cancer.
Urology. 2019
Nov 9. doi: 10.1016/j.urology.2019.10.019. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Leong JY, Herrera-Caceres JO, Goldberg H, Tham E, Teplitsky S,
Gomella LG, Trabulsi EJ, Lallas CD, Fleshner NE, Tilki D,
Chandrasekar T.
Questioning the Status Quo: Should
Gleason Grade Group 1 Prostate Cancer be Considered a "Negative
Core" in Pre-Radical Prostatectomy Risk Nomograms? An
International Multicenter Analysis.
Urology. 2019 Nov 6.
doi: 10.1016/j.urology.2019.10.012. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
TREATMENT
|
▲
|
|
De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N,
Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B,
Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De
Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S,
Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni
CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.
Metastasis-directed
Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A
Multi-institutional Analysis Comparing the Outcome and Toxicity of
Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
Eur Urol. 2019 Dec;76(6):732-739. doi:
10.1016/j.eururo.2019.07.009. Epub 2019 Jul 20.
Source
.
Similar
articles
|
|
|
|
Goy BW, Burchette R, Soper MS, Chang T, Cosmatos HA.
Ten-Year
Treatment Outcomes of Radical Prostatectomy Vs External Beam
Radiation Therapy Vs Brachytherapy for 1503 Patients With
Intermediate-risk Prostate Cancer.
Urology. 2019 Nov 5.
doi: 10.1016/j.urology.2019.09.040. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ,
Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe
VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis
BJ.
11C-Choline PET Guided Salvage
Radiation Therapy for Isolated Pelvic and Paraortic Nodal
Recurrence of Prostate Cancer After Radical Prostatectomy:
Rationale and Early Genitourinary or Gastrointestinal Toxicities.
Adv Radiat Oncol. 2019 Jul 4;4(4):659-667. doi:
10.1016/j.adro.2019.06.006.
Source
.
Similar
articles
|
|
|
|
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J,
Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ,
Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave
ME, Wyatt AW, Chi KN.
Optimal sequencing of enzalutamide
and abiraterone acetate plus prednisone in metastatic
castration-resistant prostate cancer: a multicentre, randomised,
open-label, phase 2, crossover trial.
Lancet Oncol. 2019
Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub
2019 Nov 11.
Source
.
Similar
articles
|
|
|
|
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ,
Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M,
Bryant R, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam
V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul
A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC;
ProtecT Study Group.
Ten-year Mortality, Disease
Progression, and Treatment-related Side Effects in Men with
Localised Prostate Cancer from the ProtecT Randomised Controlled
Trial According to Treatment Received.
Eur Urol. 2019
Nov 24. doi: 10.1016/j.eururo.2019.10.030. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Park J, Yoo S, Cho MC, Jeong CW, Ku JH, Kwak C, Kim HH, Jeong H.
Patients with Biopsy Gleason Score 3 + 4 Are Not
Appropriate Candidates for Active Surveillance.
Urol
Int. 2019 Nov 6:1-6. doi: 10.1159/000503888. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Valeriani M, Marinelli L, Macrini S, Reverberi C, Aschelter AM, De
Sanctis V, Marchetti P, Tronnolone L, Osti MF.
Radiotherapy
in metastatic castration resistant prostate cancer patients with
oligo-progression during abiraterone-enzalutamide treatment: a
mono-institutional experience.
Radiat Oncol. 2019 Nov
14;14(1):205. doi: 10.1186/s13014-019-1414-x.
Source
.
Similar
articles
|
|
|
|
Yoshida K, Takahashi N, Karnes RJ, Froemming AT.
Prostatic
Remnant After Prostatectomy: MR Findings and Prevalence in
Clinical Practice.
AJR Am J Roentgenol. 2020
Jan;214(1):W37-W43. doi: 10.2214/AJR.19.21345. Epub 2019 Oct 31.
Source
.
Similar
articles
|
|
|
bottom
|
▲
|
|
|